Tenofovir 1% gel

DRUG4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), CONRAD

Conditions

18-30 Years of AgeHIV InfectionsHIV NegativeHIV PreventionHigh Risk MSMRectal Microbicides

Phase 1

Tenofovir Gel in Pregnancy and Lactation

CompletedNCT01136759

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2011-03-31End: 2013-09-30Updated: 2021-10-25

Rectal Safety and Acceptability Study of Tenofovir 1% Gel

CompletedNCT01232803

CONRADRectal Microbicides

Start: 2010-10-31End: 2011-07-31Updated: 2021-06-28

Microbicide Safety and Acceptability in Young Men

CompletedNCT01283360

CONRAD18-30 Years of Age, High Risk MSM, HIV Negative

Start: 2010-10-31End: 2013-05-31Updated: 2015-05-28

In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products

CompletedNCT01813162

CONRADHIV Prevention

Start: 2013-12-31End: 2014-12-31Updated: 2015-05-22

Related Papers

Mucosal tenofovir 1% gel stimulates cell proliferation and type I/III interferon pathways.

2026-03-23

Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women

PLoS ONE2016-06-3015 citations

A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007).

2013-04-0381 citations